Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators

Journal of Medicinal Chemistry

Volumn 56, Issue 22, 2013, Pages 9180-9191

  Patel, Nandini C ^a   Schwarz, Jacob ^b   Hou, Xinjun J ^a   Hoover, Dennis J ^a   Xie, Longfei ^a   Fliri, Anton J ^a   Gallaschun, Randall J ^a   Lazzaro, John T ^a   Bryce, Dianne K ^c   Hoffmann, William E ^a   Hanks, Ashley N ^a   McGinnis, Dina ^d   Marr, Eric S ^a   Gazard, Justin L ^a   Hajós, Mihály ^e   Scialis, Renato J ^a   Hurst, Raymond S ^f   Shaffer, Christopher L ^a   Pandit, Jayvardhan ^a   O'Donnell, Christopher J ^a  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMPA RECEPTOR AGONIST; ANILINE; CYCLIC GMP; GLUTAMIC ACID; GSK 729327; GSK 732973; LY 2059346; N [2 [4 (4 CYANOPHENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; PF 04701475; PF 04725379; UNCLASSIFIED DRUG;

ABSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING ASSAY; BRAIN HOMOGENATE; CONTROLLED STUDY; CONVULSION; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LIVER CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEUROTOXICITY; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY CRYSTALLOGRAPHY;

ABSORPTION; ALLOSTERIC REGULATION; ANIMALS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOXAZOLES; MALE; MICE; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, AMPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84889254433     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401274b     Document Type: Article

References (58)

1. Parsons, C. G.; Danysz, W.; Zieglgaensberger, W. Excitatory amino acid neurotransmission Handb. Exp. Pharmacol. 2005, 169, 249-303 Anxiety and Anxiolytic Drugs
2. Lynch, G. Memory enhancement: the search for mechanism-based drugs Nat. Neurosci. 2002, 5 (Suppl) 1035-1038 (Pubitemid 35247193)
3. Malinow, R.; Malenka, R. C. AMPA receptor trafficking and synaptic plasticity Annu. Rev. Neurosci. 2002, 25, 103-126 (Pubitemid 34748013)
4. Lynch, G.; Gall, C. M. Ampakines and the threefold path to cognitive enhancement Trends Neurosci. 2006, 29, 554-562 (Pubitemid 44416457)
5. Morris, R. G. M. Long-term potentiation and memory Philos. Trans. R. Soc. London B 2003, 358, 643-647 (Pubitemid 36536693)
6. Kinney, G. G.; Patino, P.; Mermet-Bouvier, Y.; Starrett, J. E., Jr.; Gribkoff, V. K. Cognition-enhancing drugs increase stimulated hippocampal θ rhythm amplitude in the urethane-anesthetized rat J. Pharmacol. Exp. Ther. 1999, 291, 99-106 (Pubitemid 29451578)
7. Hampson, R. E.; Espana, R. A.; Rogers, G. A.; Porrino, L. J.; Deadwyler, S. A. Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717 Psychopharmacology 2009, 202, 355-369
8. Roberts, B. M.; Holden, D. E.; Shaffer, C. L.; Seymour, P. A.; Menniti, F. S.; Schmidt, C. J.; Williams, G. V.; Castner, S. A. Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction Behav. Brain Res. 2010, 212, 41-48
9. Black, M. D. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data Psychopharmacology 2005, 179, 154-163 (Pubitemid 40584805)
10. Marenco, S.; Weinberger, D. R. Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders CNS Drugs 2006, 20, 173-185
11. O'Neill, M. J.; Bleakman, D.; Zimmerman, D. M.; Nisenbaum, E. S. AMPA receptor potentiators for the treatment of CNS disorders Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 181-194 (Pubitemid 38854913)
12. Gainetdinov, R. R.; Mohn, A. R.; Bohn, L. M.; Caron, M. G. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 11047-11054 (Pubitemid 32928681)
13. Traynelis, S. F.; Wollmuth, L. P.; McBain, C. J.; Menniti, F. S.; Vance, K. M.; Ogden, K. K.; Hansen, K. B.; Yuan, H.; Myers, S. J.; Dingledine, R. Glutamate receptor ion channels: structure, regulation, and function Pharmacol. Rev. 2010, 62, 405-496
14. Wisden, W.; Seeburg, P. H. Mammalian ionotropic glutamate receptors Curr. Opin. Neurobiol. 1993, 3, 291-298 (Pubitemid 23210937)
15. Monyer, H.; Seeburg, P. H.; Wisden, W. Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing Neuron 1991, 6, 799-810
16. Pei, W.; Huang, Z.; Wang, C.; Han, Y.; Park, J. S.; Niu, L. Flip and Flop: A Molecular Determinant for AMPA Receptor Channel Opening Biochemistry 2009, 48, 3767-3777
17. Hansen, K. B.; Yuan, H.; Traynelis, S. F. Structural aspects of AMPA receptor activation, desensitization and deactivation Curr. Opin. Neurobiol. 2007, 17, 281-288 (Pubitemid 46880320)
18. Mayer, M. L. Glutamate receptors at atomic resolution Nature 2006, 440, 456-462
19. Jin, R.; Banke, T. G.; Mayer, M. L.; Traynelis, S. F.; Gouaux, E. Structural basis for partial agonist action at ionotropic glutamate receptors Nat. Neurosci. 2003, 6, 803-810 (Pubitemid 36929700)
20. Partin, K. M.; Fleck, M. W.; Mayer, M. L. AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate J. Neurosci. 1996, 16, 6634-6647 (Pubitemid 26359347)
21. Grove, S. J. A.; Jamieson, C.; Maclean, J. K. F.; Morrow, J. A.; Rankovic, Z. Positive allosteric modulators of the α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) receptor J. Med. Chem. 2010, 53, 7271-7279
22. Lynch, G.; Kessler, M.; Rogers, G.; Ambros-Ingerson, J.; Granger, R.; Schehr, R. S. Psychological effects of a drug that facilitates brain AMPA receptors Int. Clin. Psychopharmacol. 1996, 11, 13-19 (Pubitemid 26135298)
23. Granger, R.; Staubli, U.; Davis, M.; Perez, Y.; Nilsson, L.; Rogers, G. A.; Lynch, G. A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task Synapse 1993, 15, 326-329
24. Rosi, S.; Grazia Giovannini, M.; Lestage, P. J.; Munoz, C.; Della Corte, L.; Pepeu, G. S18986, a positive modulator of AMPA receptors with cognition-enhancing properties, increases ACh release in the hippocampus of young and aged rat Neurosci. Lett. 2004, 361, 120-123 (Pubitemid 38609231)
25. Ward, S. E.; Harries, M.; Aldegheri, L.; Austin, N. E.; Ballantine, S.; Ballini, E.; Bradley, D. M.; Bax, B. D.; Clarke, B. P.; Harris, A. J.; Harrison, S. A.; Melarange, R. A.; Mookherjee, C.; Mosley, J.; Dal Negro, G.; Oliosi, B.; Smith, K. J.; Thewlis, K. M.; Woollard, P. M.; Yusaf, S. P. Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators J. Med. Chem. 2011, 54, 78-94
26. Ornstein, P. L.; Zimmerman, D. M.; Arnold, M. B.; Bleisch, T. J.; Cantrell, B.; Simon, R.; Zarrinmayeh, H.; Baker, S. R.; Gates, M.; Tizzano, J. P.; Bleakman, D.; Mandelzys, A.; Jarvie, K. R.; Ho, K.; Deverill, M.; Kamboj, R. K. Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid (AMPA) receptors J. Med. Chem. 2000, 43 (23) 4354-4358 (Pubitemid 32046858)
27. Zarrinmayeh, H.; Tromiczak, E.; Zimmerman, D. M.; Rankl, N.; Ho, K. H.; Dominguez, E.; Castano, A.; Escribano, A.; Fernandez, C.; Jimenez, A.; Hornback, W. J.; Nisenbaum, E. S. A novel class of positive allosteric modulators of AMPA receptors: design, synthesis, and structure-activity relationships of 3-biphenyl-4-yl-4-cyano-5-ethyl-1-methyl-1 H -pyrrole-2-carboxylic acid, LY2059346 Bioorg. Med. Chem. Lett. 2006, 16, 5203-5206 (Pubitemid 44247689)
28. Ward, S. E.; Harries, M.; Aldegheri, L.; Andreotti, D.; Ballantine, S.; Bax, B. D.; Harris, A. J.; Harker, A. J.; Lund, J.; Melarange, R.; Mingardi, A.; Mookherjee, C.; Mosley, J.; Neve, M.; Oliosi, B.; Profeta, R.; Smith, K. J.; Smith, P. W.; Spada, S.; Thewlis, K. M.; Yusaf, S. P. Discovery of N -[(2 S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1 H -inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator J. Med. Chem. 2010, 53, 5801-5812
29. Zarrinmayeh, H.; Bleakman, D.; Gates, M. R.; Yu, H.; Zimmerman, D. M.; Ornstein, P. L.; McKennon, T.; Arnold, M. B.; Wheeler, W. J.; Skolnick, P. [3 H ] N -2-(4-(N -benzamido)phenyl)propyl-2- propanesulfonamide: a novel AMPA receptor potentiator and radioligand J. Med. Chem. 2001, 44, 302-304 (Pubitemid 32113580)
30. McNeish, J.; Roach, M.; Hambor, J.; Mather, R. J.; Weibley, L.; Lazzaro, J.; Gazard, J.; Schwarz, J.; Volkmann, R.; Machacek, D.; Stice, S.; Zawadzke, L.; O'Donnell, C.; Hurst, R. High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of α-amino-3-hydroxyl-5- methyl-4-isoxazolepropionate-type glutamate receptors J. Biol. Chem. 2010, 285, 17209-17217
31. Barbachyn, M. R.; Ford, C. W. Oxazolidinone structure-activity relationships leading to linezolid Angew. Chem., Int. Ed. 2003, 42, 2010-2023 (Pubitemid 36604340)
32. Barbachyn, M. R.; Cleek, G. J.; Dolak, L. A.; Garmon, S. A.; Morris, J.; Seest, E. P.; Thomas, R. C.; Toops, D. S.; Watt, W.; Wishka, D. G.; Ford, C. W.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert, D.; Yagi, B. H.; Adams, W. J.; Friis, J. M.; Slatter, J. G.; Sams, J. P.; Oien, N. L.; Zaya, M. J.; Wienkers, L. C.; Wynalda, M. A. Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens J. Med. Chem. 2003, 46, 284-302 (Pubitemid 36078146)
33. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449
34. Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution Drug Discovery Today: Technol. 2004, 1, 337-341 (Pubitemid 40186335)
35. Hop, C. E. C. A.; Cole, M. J.; Davidson, R. E.; Duignan, D. B.; Federico, J.; Janiszewski, J. S.; Jenkins, K.; Krueger, S.; Lebowitz, R.; Liston, T. E.; Mitchell, W.; Snyder, M.; Steyn, S. J.; Soglia, J. R.; Taylor, C.; Troutman, M. D.; Umland, J.; West, M.; Whalen, K. M.; Zelesky, V.; Zhao, S. X. High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models Curr. Drug Metab. 2008, 9, 847-853
36. Timm, D. E.; Benveniste, M.; Weeks, A. M.; Nisenbaum, E. S.; Partin, K. M. Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation Mol. Pharmacol. 2011, 80, 267-280
37. Sun, Y.; Olson, R.; Horning, M.; Armstrong, N.; Mayer, M.; Gouaux, E. Mechanism of glutamate receptor desensitization Nature 2002, 417, 245-253 (Pubitemid 34534700)
38. Jin, R.; Clark, S.; Weeks, A. M.; Dudman, J. T.; Gouaux, E.; Partin, K. M. Mechanism of positive allosteric modulators acting on AMPA receptors J. Neurosci. 2005, 25, 9027-9036 (Pubitemid 41384472)
39. Ahmed, A. H.; Ptak, C. P.; Oswald, R. E. Molecular mechanism of flop selectivity and subsite recognition for an AMPA receptor allosteric modulator: structures of GluA2 and GluA3 in complexes with PEPA Biochemistry 2010, 49, 2843-2850
40. Marrone, T. J.; Luty, B. A.; Rose, P. W. Discovering high-affinity ligands from the computationally predicted structures and affinities of small molecules bound to a target: a virtual screening approach Perspect. Drug Discovery Des. 2000, 20, 209-230
41. Gehlhaar, D. K.; Verkhivker, G. M.; Rejto, P. A.; Sherman, C. J.; Fogel, D. B.; Fogel, L. J.; Freer, S. T. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming Chem. Biol. 1995, 2, 317-324
42. Linden, A. M.; Yu, H.; Zarrinmayeh, H.; Wheeler, W. J.; Skolnick, P. Binding of an AMPA receptor potentiator ([3H]LY395153) to native and recombinant AMPA receptors Neuropharmacology 2001, 40, 1010-1018 (Pubitemid 32530607)
43. Stepan, A. F.; Walker, D. P.; Bauman, J.; Price, D. A.; Baillie, T. A.; Kalgutkar, A. S.; Aleo, M. D. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 2011, 24, 1345-1410
44. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.; Nakai, Y.; O'Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 2005, 6, 161-225 (Pubitemid 40753853)
45. Tillement, J. P.; Urien, S.; Chaumet-Riffaud, P.; Riant, P.; Bree, F.; Morin, D.; Albengres, E.; Barre, J. Blood binding and tissue uptake of drugs. Recent advances and perspectives Fundam. Clin. Pharmacol. 1988, 2, 223-238
46. Shaffer, C. L. Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposure-response relationships Annu. Rep. Med. Chem. 2010, 45, 55-70
47. Liu, X.; Van Natta, K.; Yeo, H.; Vilenski, O.; Weller, P. E.; Worboys, P. D.; Monshouwer, M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid Drug Metab. Dispos. 2009, 37, 787-793
48. Doran, A. C.; Osgood, S. M.; Mancuso, J. Y.; Shaffer, C. L. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations Drug Metab. Dispos. 2012, 40, 2162-2173
49. Yamada, K. A. Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Neurobiol. Dis. 1998, 5, 67-80 (Pubitemid 28430717)
50. Garthwaite, G. G. Mechanisms of AMPA neurotoxicity in rat brain slices Eur. J. Neurosci. 1991, 3, 729-736
51. Di, L.; Umland, J. P.; Chang, G.; Huang, Y.; Lin, Z.; Scott, D. O.; Troutman, M. D.; Liston, T. E. Species independence in brain tissue binding using brain homogenates Drug Metab. Dispos. 2011, 39, 1270-1277
52. Shaffer, C. L.; Hurst, R. S.; Scialis, R. J.; Osgood, S. M.; Bryce, D. K.; Hoffmann, W. E.; Lazzaro, J. T.; Hanks, A. N.; Lotarski, S.; Weber, M. L.; Liu, J.; Menniti, F. S.; Schmidt, C. J.; Hajós, M. Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574 J. Pharmacol. Exp. Ther. 2013, 347, 212-224
53. Ryder, J. W.; Falcone, J. F.; Manro, J. R.; Svensson, K. A.; Merchant, K. M. Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors J. Pharmacol. Exp. Ther. 2006, 319, 293-298 (Pubitemid 44455135)
54. Kiss, T.; Hoffmann, W. E.; Hajos, M. Delta oscillation and short-term plasticity in the rat medial prefrontal cortex: modelling NMDA hypofunction of schizophrenia Int. J. Neuropsychopharmacol. 2011, 14, 29-42
55. Olney, J. W.; Newcomer, J. W.; Farber, N. B. NMDA receptor hypofunction model of schizophrenia J. Psychiatr. Res. 1999, 33, 523-533
56. Goldman-Rakic, P. S. Working memory dysfunction in schizophrenia J. Neuropsychiatry Clin. Neurosci. 1994, 6, 348-357 (Pubitemid 24344855)
57. Moghaddam, B.; Javitt, D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment Neuropsychopharmacology 2012, 37, 4-15
58. max variability after an oral dose via PBPK modeling Biopharm. Drug Dispos. 2012, 33, 72-84